Newsletter | December 17, 2025

12.17.25 -- Why Feasibility Still Feels Broken

SPONSOR

Measuring patient-reported tolerability in oncology trials

January 28: Join experts from University of Birmingham, Takeda, and Signant Health for a live online discussion about patient-reported tolerability assessment across oncology development phases. You'll learn why traditional adverse event reporting falls short, and how patient-centered tolerability assessment enhances dose-finding decisions and strengthens regulatory submissions. Plus, get practical frameworks for integrating PROs across oncology development phases. Get the details and save your spot today.

DECENTRALIZED TRIALS

Trends In Rare Disease Trials

In the third article of this series, analyst reveal their top six recommendations for designing selection criteria and selecting solution options to optimize rare disease research outcomes.

Community And Decentralized Approaches In Women’s Healthcare

If a condition affects more women than men, trials should reflect this by reducing participation barriers and bringing studies to patients to improve inclusion and real-world data.

Top 10 Challenges And Solutions For Decentralized Clinical Trials

Decentralized clinical trials are reshaping research, but what are the biggest roadblocks to their full potential? We delve into the top 10 challenges and the cutting-edge solutions emerging.

Direct-To-Patient Supply: Industry Perception And Future Trends

To better understand sponsors’ perspectives on DTP distribution of clinical supplies, 234 individuals involved in clinical supply and operations were recently surveyed. Click to get the results!

TRIAL MANAGEMENT

Why Feasibility Still Feels Broken

Addressing feasibility requires more than process tweaks; it demands better communication, streamlined data collection, and collaborative planning to ensure sites are equipped to deliver. Access the full article to learn why feasibility still feels broken and explore practical strategies to improve accuracy, reduce burden, and strengthen site-sponsor relationships.

Cognitive, Pharmacodynamic Testing During FIH CNS Trials

A comprehensive review of optimal timing and methodologies for cognitive and pharmacodynamic testing during first-in-human trials on CNS-active compounds.

Pioneering Strategies For Early-Phase Oncology Trials

Adaptive methods and regulatory shifts are reshaping early-phase oncology trials, boosting efficiency, flexibility, and access so novel treatments reach patients faster and more effectively.

Fortrea Optimizes Site Matching On Retina Clinical Trials

Faced with challenges in engaging clinical trial sites within the retina research landscape, Fortrea sought a partnership that leverages RWD to streamline site feasibility assessments.

What Everest Group's RTSM Recognition Means For The Industry

RTSM is transforming from a basic operational tool into a strategic driver of trial efficiency. Learn why industry recognition signals a new era of innovation and competitive advantage.

Preliminary Budgeting + MedSci Consulting Services, For Free

Are you still in doubt about your study protocol or how to determine the sample size? Gain access to free clinical trial budgeting and MedSci consulting services from a leading Eastern European CRO.

CHOOSE YOUR OWN ADVENTURE

You're receiving the Wednesday edition of the Clinical Leader newsletter, focusing on Decentralized Trials and Trial Management. To make changes to your newsletter selections, update your topic preferences.

  • Clinical Sites | Patient Centricity | Patient Recruitment (Monday)
  • Clinical Trial Technology (Tuesday)
  • Decentralized Trials | Trial Management (Wednesday)
  • Outsourcing Models | Regulatory & Compliance (Thursday)
  • Clinical Data Management & Analytics | Trial Monitoring (Friday)

Learn more about our personalized newsletters here.

Connect With Clinical Leader: